Arvinas, Inc. - Common Stock — Cash Flow (NASDAQ:ARVN) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -89.76 M559.4 M-273.5 M-347.8 M-259.3 M-273.8 M -207 M Cash from investing activities 164.25 M-1.31 B242.8 M203.5 M34.7 M407.6 M 277.9 M Cash from financing activities 504.67 M278.6 M4.7 M374.7 M7.9 M-91.4 M -91.5 M Free cash flow -89.76 M559.4 M-273.5 M-347.8 M-259.3 M-275.7 M -208.8 M

News

Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish (NASDAQ:ARVN)

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL)

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

Is Kymera Therapeutics Poised for a Breakthrough With KT-621?

A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)

uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential (NASDAQ:GLUE)

These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Arvinas (NASDAQ:ARVN), Pfizer (NYSE

Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript

Arvinas: FDA Approval Validates The Platform, But Does Not Signal Near-Term Profitability